Use of a neurofilament peptide for the treatment of glioma
AssigneesUniversite D'Angers, Institu National De La Sante Et De La Recherche Medicale (Inserm), The Royal Institution for the Advancement of Learning/Mcgill University
InventorsJoel Eyer, Alan Peterson, Julien Balzeau, Raphael Berges
Life of this patent
Estimating the term…
Abstract
The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
Claims5
-17. (canceled)
A method for addressing or targeting a chemical compound to glioma cells in vivo in a subject in need thereof, or in vitro, comprising the step of providing an amino acid sequence comprising the NFL-TBS40-63 peptide (SEQ ID NO:
- 1) or a biologically active derivative thereof.
Dependencies are inferred from the claim text.